Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    K-321
Previous Study | Return to List | Next Study

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04250207
Recruitment Status : Active, not recruiting
First Posted : January 31, 2020
Last Update Posted : December 2, 2021
Sponsor:
Information provided by (Responsible Party):
Kowa Research Institute, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.

Condition or disease Intervention/treatment Phase
Fuchs' Endothelial Corneal Dystrophy Drug: K-321 Solution Drug: Placebo Solution Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Masked, Randomised, Placebo-Controlled, Parallel-Group, 12 Week, Phase 2 Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Patients With Fuchs Endothelial Corneal Dystrophy
Actual Study Start Date : June 23, 2020
Actual Primary Completion Date : September 22, 2021
Estimated Study Completion Date : July 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: K-321 QID
K-321 Ophthalmic Solution Dose A
 Drug: K-321 Solution
K-321 solution drops
Experimental: K-321 BID
K-321 Ophthalmic Solution Dose B
 Drug: K-321 Solution
K-321 solution drops

Drug: Placebo Solution
Placebo solution drops for K-321
Placebo Comparator: Placebo
Vehicle Solution Dose
 Drug: Placebo Solution
Placebo solution drops for K-321


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Corneal Central ECD Measure at 12 weeks [ Time Frame: 12 Weeks ]
    Change in Central Endothelial Cell Density


Secondary Outcome Measures :
  1. Safety Assessment [ Time Frame: 52 Weeks ]
    Number of participants with at least one adverse event


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Is at least 18 years old at the screening visit (Visit 1).
  • Has a diagnosis of FECD at Visit 1.
  • Meet all other inclusion criteria outlined in clinical study protocol.

Exclusion Criteria:

  • Has a study eye with a history of cataract surgery within 90 days of Visit 1.
  • Has a study eye with a history of any previous ocular surgery other than for cataract.
  • Meet any other exclusion criteria outlined in clinical study protocol.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04250207


Locations
Show Show 28 study locations
Sponsors and Collaborators
Kowa Research Institute, Inc.
Investigators
Layout table for investigator information
Study Chair: Shona Pendse, MD, MMSc Kowa Pharma Development Co.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Kowa Research Institute, Inc.
ClinicalTrials.gov Identifier: NCT04250207    
Other Study ID Numbers: K-321-201
First Posted: January 31, 2020    Key Record Dates
Last Update Posted: December 2, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Corneal Dystrophies, Hereditary
Iridocorneal Endothelial Syndrome
Fuchs' Endothelial Dystrophy
Corneal Diseases
Eye Diseases
 Eye Diseases, Hereditary
Genetic Diseases, Inborn
Iris Diseases
Uveal Diseases
Pharmaceutical Solutions